Identification of potent and novel small-Molecule inhibitors of caspase-3

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 21, 2003, Pages 3651-3655

  Allen, Darin A ^a   Pham, Phuongly ^a   Choong, Ingrid C ^a   Fahr, Bruce ^a   Burdett, Matthew T ^a   Lew, Willard ^a   DeLano, Warren L ^a   Gordon, Eric M ^a   Lam, Joni W ^a   O'Brien, Tom ^a   Lee, Dennis ^a,b  

^a Sunesis Pharmaceuticals Inc   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZENE DERIVATIVE; CASPASE 3; CASPASE 3 INHIBITOR; SALICYLIC ACID DERIVATIVE; THIOPHENE DERIVATIVE;

ARTICLE; DRUG DESIGN; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN;

EID: 12444252935     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.08.024     Document Type: Article

References (19)

1. (a) McBride C.B., McPhail L.T., Steeves J.D. Emerg. Therap. Targets. 3:1999;391
2. (b) Earnshaw W.C., Martins L.M., Kaufman S.H. Annu. Rev. Biochem. 68:1999;383
3. (c) Salvesen G.S., Denault J.B. Chem. Rev. 102:2002;4489.
4. Tethering is a service mark of Sunesis Pharmaceuticals for its fragment-based drug discovery.
5. (a) Choong I.C., Lew W., Lee D., Pham P., Burdett M.T., Lam J.W., Wiesmann C., Luong T.N., Fahr B., DeLano W.L., McDowell R.S., Allen D.A., Erlanson D.E., Gordon E.M., O'Brien T. J. Med. Chem. 45:2002;5005
6. (b) Erlanson D.E., Lam J.W., Wiesmann C., Luong T.N., Simmons R.L., DeLano W.L., Choong I.C., Burdett M.T., Flanagan W.M., Lee D., Gordon E.M., O'Brien T. Nat. Biotechnol. 2003;308.
7. Batchelor, J. B.; Drewe, J.; Wang, Y.; Weber, E.; Bebbington, D.; Bemis, G. W.; Fridman, W. H.; Gillespie, R. J.; Golec, J. M. C.; Lauffer, D. J.; Livingston, D. J.; Matharu, S. S.; Mullican, M. D.; Murcko, M. A.; Murdoch, R.; Zelle, R. E. US Patent 6,204,261 B1, 2001.
8. Karanewsky, D. S.; Kalish, V. J.; Robinson, E. D.; Ullman, B. R. WO0023421, 2000.
9. Widmer U. Synthesis. 1983;135.
10. Wright S.W., Hageman D.L., Wright A.S., McClure L.D. Tetrahedron Lett. 38:1997;7345.
11. Jones T.R., Varney M.D., Webber S.E., Lewis K.K., Marzoni G.P., Palmer C.L., Kathardekar V., Welsh K.M., Webber S., Matthews D.A., Appelt K., Smith W.W., Janson C.A., Villafranca J.E., Bacquet R.J., Howland E.F., Booth C.L.J., Herrmann S.M., Ward R.W., White J., Moomaw E.W., Bartlett C.A., Morse C.A. J. Med. Chem. 39:1996;904.
12. Mjalli A.M., Chapman K.T., MacCoss M., Thornberry N.A. Bioorg. Med. Chem. Lett. 3:1993;2689.
13. Bemis, G. W.; Golec, J. M. C.; Lauffer, D. J.; Mullican, M. D.; Murcko, M. A.; Livingston, D. J. US Patent 6,103,711, 2000.
14. Moradi W.A., Buchwald S.L. J. Am. Chem. Soc. 123:2001;7996.
15. Garvey E.P., Oplinger J.A., Tanoury G.J., Sherman P.A., Fowler M., Marshal S., Harmon M.F., Paith J.E., Furfine E.S. J. Biol. Chem. 269:1994;26669.
16. Graphics produced using PyMol v. 0.86; DeLano Scientific LLC; San Carlos, CA, USA; http://www.pymol.org.
17. Kohara Y., Kubo K., Imamiya E., Wada T., Inada Y., Naka T. J. Med. Chem. 39:1996;5228.
18. a of 3-phenyl-1,2,4-oxadiazol-5(4H)-one has been reported as 5.06; see: Ponzio G., Zanardi-Lamberti B. Gazz. Chim. Ital. 53:1923;821.
19. Representative analogues were tested for reversible inhibition by incubation of compound with Caspase-3 followed by analysis by MS.